Case studies › NTRA
Natera's $6bn target is a 2026 number being paid for in 2026
Natera put a US$6 billion revenue target on 2029 and raised 2026 guidance in the same call. The company was explicit that the target comes from commercial execution in molecular residual disease, not from the screening products still in trials. That candour is worth taking literally.
Third-quarter revenue was US$794 million, up 34.1%. The adjusted loss was 39 cents against a 17 cent consensus loss. Gross margin was 64.7%, or 63.2% excluding revenue true-ups.
The bridge, as management modelled it
| Input | Value |
|---|---|
| 2029 revenue target | $6.0bn |
| 2026 revenue guide (raised) | $3.005–3.035bn |
| Signatera ASP assumed | ~$1,450 |
| Signatera ASP current | ~$1,290 |
| Q3 clinical MRD volume | 316,000 units |
| Q3 volume growth | +56% |
| Q3 sequential volume added | +33,000 units |
| Gross margin guide | 64–66% |
The target is achievable, management said, at an ASP near US$1,450 against about US$1,290 now. That is an 11% price increase assumed into the plan, which is the least discussed part of it.
Units, price, and which one is doing the work
At US$1,290 and US$6 billion, the 2029 volume requirement is roughly 4.65 million tests a year. Against a current quarterly run rate of 316,000, or about 1.26 million annualised, that is between three and four times current volume by 2029.
At US$1,450 the requirement falls to about 4.14 million. So the price assumption removes around half a million tests from the plan. It is not a rounding item.
The volume growth is real: 56% year over year, with 33,000 units added sequentially. Colorectal and breast remained the largest indications, and adoption broadened across additional tumour types. If the 56% holds, 2029 volume is reached by arithmetic without any of the price.
The reimbursement gate
New Medicare coverage exists for serial testing in early-stage hepatocellular carcinoma surveillance. Nine or ten further MolDX submissions remain under review, with management confident on the evidence and silent on timing.
MolDX is the gate on the price assumption. An ASP of US$1,450 is a coverage outcome, not an operating decision, and ten submissions under review is ten chances for a partial answer. Japan adds a bladder cancer approval with colorectal and bladder reimbursement still in discussion and terms unresolved.
The spend side
2026 revenue guidance was raised by US$140 million at the midpoint, and the upper limits of R&D and SG&A were raised with it, to US$925 million and US$1.3 billion. Gross margin guidance was held at 64% to 66%.
Operating expense growth of 10% to 12% is projected for 2027. Against 34% revenue growth that is positive operating leverage, but the higher spend ceilings sit in pharma services and clinical trials, which are the parts that feed the pipeline rather than the current quarter.
At a 39 cent quarterly loss against revenue of US$794 million, the company is not near breakeven, and the raised guidance did not move margin. Revenue growth is buying the loss.
Where the case breaks
The plan requires an 11% price increase on a test whose coverage is still being adjudicated in nine or ten open submissions. A single adverse MolDX determination compresses the 2029 revenue target toward the volume-only case, which is a lower number reached later.
The second break is volume concentration. Colorectal and breast are the largest indications and both are crowded. A share loss in either removes units faster than a new tumour type adds them.
The third is the leadership change: the incoming chief executive inherits the target while the outgoing one moves to a consultancy and board role. Continuity was asserted rather than demonstrated.
What the arithmetic says
Revenue up 34.1% and the loss nearly double consensus, with the target resting on 3.65 times current volume and an 11% price rise, gated by ten coverage decisions and funded by an expense line being raised alongside the sales line.
US$6 billion by 2029 needs 4.65 million tests a year at today's price. The plan assumes US$1,450, which is half a million tests cheaper — and which ten unreviewed submissions have to grant.
Sources
Revenue, loss, margin, volume, ASP, guidance, expense ceilings, coverage status, trial enrolment and leadership changes are the company's own third-quarter 2026 results and call disclosures. Consensus figures are third-party. Volume requirements at both ASPs are arithmetic on the stated target, price and run rate, and can be re-run.
Published for information only. Nothing here is investment advice or a recommendation. This note is not prepared in accordance with the legal requirements designed to promote the independence of investment research. No position is held in the security covered.